CDNA and positivity are a hazardous promising biomarker for MLT unit status. A previous study demonstrated the association between MLT positivity and recurrence risk. However, only a few data are available in venous recurrent genome. So we launched a prospective multi-center trial, also a screening trial, which performs ultra-sensitive next-generation sequence-based MLDR assay in solid tumors...
CDNA and positivity are a hazardous promising biomarker for MLT unit status. A previous study demonstrated the association between MLT positivity and recurrence risk. However, only a few data are available in venous recurrent genome. So we launched a prospective multi-center trial, also a screening trial, which performs ultra-sensitive next-generation sequence-based MLDR assay in solid tumors. So as a result, we can, you know, detect 100% positivity at baseline and at 11.1% at one month post-surgery with 50 percent detectable at ultra-sensitive levels and also we found ctDNA levels were closely associated with, you know, stage or tumor size or, you know, lymph node status and finally we found that patients with recurrent disease had persisted ctDNA-positive after the surgery. So in the end, all together, these findings indicate that a next-generation sequence-based approach is very feasible and may predict recurrence after the surgery in the audits and bibliographic examinations.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
